GlassScriptPhysician profile
Joshua B Campo
NPI 1790289577
$9,534.06
in general payments reported to CMS, 2019-2025
40 companies · $3,301 in 2025
The $3,301 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.01 · 2021: $38.62 · 2022: $1,122 · 2023: $1,892 · 2024: $3,157 · 2025: $3,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,349.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,254.63 | 2022-2025 | Ubrelvy, Botox, Duopa |
| Ucb, INC. | $958.59 | 2023-2025 | Briviact, Nayzilam, Fintepla |
| Neurelis, INC. | $622.74 | 2022-2025 | Valtoco |
| Argenx US, INC. | $593.37 | 2022-2025 | Vyvgart Hytrulo |
| Lundbeck LLC | $516.36 | 2023-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $477.56 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $461.21 | 2024-2025 | Nuplazid |
| Lilly USA, LLC | $377.79 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $375.98 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Sk Life Science, INC. | $363.67 | 2022-2023 | |
| Eisai INC. | $350.72 | 2023-2025 | |
| Pfizer INC. | $335.94 | 2023-2025 | |
| Grifols USA, LLC | $305.84 | 2023-2025 | Gamunex-C |
| Alexion Pharmaceuticals, INC. | $274.99 | 2021-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $249.88 | 2024-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $206.26 | 2023-2025 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $205.19 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $155.82 | 2022-2025 | Austedo Xr, Ajovy, Austedo |
| Genentech USA, INC. | $141.39 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $131.81 | 2022-2025 | Hyqvia, Gammagard |
| Amgen INC. | $131.58 | 2022-2025 | Uplizna |
| Jazz Pharmaceuticals INC. | $124.99 | 2023 | Epidiolex |
| Amneal Pharmaceuticals LLC | $114.57 | 2023-2025 | Rytary, Ongentys |
| Celgene Corporation | $86.63 | 2024-2025 | Zeposia |
| Vanda Pharmaceuticals INC. | $83.92 | 2025 | Ponvory |
| Tg Therapeutics, INC. | $78.63 | 2023-2025 | |
| Sarepta Therapeutics, INC. | $58.16 | 2023 | |
| Scilex Pharmaceuticals INC. | $55.88 | 2024-2025 | |
| Janssen Biotech, INC. | $53.27 | 2025 | |
| Ge Healthcare | $52.32 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $51.39 | 2022-2024 | Wainua |
| Csl Behring | $39.49 | 2025 | Hizentra |
| Horizon Therapeutics Plc | $37.36 | 2023 | Uplizna |
| Merz Pharmaceuticals, LLC | $36.59 | 2025 | Xeomin, Inbrija, Ampyra |
| Neurocrine Biosciences, INC. | $28.90 | 2022 | |
| Aucta Pharmaceuticals, INC. | $27.52 | 2024-2025 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $21.51 | 2025 | Tascenso Odt |
| Azurity Pharmaceuticals, INC. | $19.53 | 2025 | Horizant |
| Idorsia Pharmaceuticals US INC | $15.90 | 2023 | Quviviq |
| Boston Scientific Corporation | $15.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Campo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.